WIN-Partners Co., Ltd. Second Quarter Financial Summary [Japanese GAAP] (Consolidated)

Overview of Performance

During this interim period, net sales expanded steadily year-over-year, supported by increased shipment volumes in the Company’s core ischemic heart disease-related, cardiac rhythm management-related, and cardiovascular surgery-related products, together with growth in medical device-related sales. Operating income, ordinary income and interim net income all exceeded the prior-year period, with a notable shift in sales composition toward medical device-related products. In the second half, impacts from financing activities (including items related to dividends) will also be taken into account. The financial summary includes the interim financial position, consolidated financial statements and notes.

Outlook and Dividends

There is no change to the full-year consolidated earnings forecast announced on May 15, 2026: net sales 100,000 hundred million yen, operating income 3,350 million yen, ordinary income 3,380 million yen, net income attributable to owners of parent 2,210 million yen, and earnings per share 80.37 yen. Annual dividend is currently expected to be 55.00 yen. The dividend at the end of the second quarter is 0 yen.